As part of its R&D restructuring, Merck & Co. Inc. (NYSE:MRK) said it would focus on four therapeutic areas - oncology, acute hospital care, vaccines and diabetes - and reduce its reliance on platforms. So far, it is unclear which of the company's recent platform deals might be affected. The pharma has done at least 13 such deals since 2011. At least one of the partnerships falls outside Merck's new focus areas - a July deal to